CSIMarket Company Name, Ticker, Suppliers, else..
 
Aeterna Zentaris Inc   (NASDAQ: AEZS)
Other Ticker:  
 
 
Price: $5.7200 $0.32 5.926%
Day's High: $6.2 Week Perf: -3.46 %
Day's Low: $ 5.48 30 Day Perf: 8.95 %
Volume (M): 8 52 Wk High: $ 11.10
Volume (M$): $ 43 52 Wk Avg: $7.18
Open: $5.51 52 Wk Low: $1.95



 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 1
 Employees 35
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 51
 Capital Exp. (TTM) (Millions $) 0

Aeterna Zentaris Inc
Aeterna Zentaris Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments in oncology and endocrinology. It is based in Canada and operates globally. The company's research and development efforts are aimed at discovering novel therapeutic solutions for cancer and hormonal diseases. Aeterna Zentaris Inc aims to improve patients' lives through the development of effective and safe treatments.


   Company Address: c/o Norton Rose Fulbright Canada, LLP Toronto 0 ON
   Company Phone Number:    Stock Exchange / Ticker: NASDAQ AEZS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABVC      % 
CING      % 
INBP        16.89% 
IRWD        16.89% 
TLPH        16.89% 
VERU        16.89% 
• View Complete Report
   



Stocks on the Move

Aeterna Zentaris Inc Shows Positive Momentum in Recent Trading Period

Published Thu, Aug 15 2024 9:41 AM UTC

Aeterna Zentaris Inc, a specialty biopharmaceutical company, has witnessed notable developments and movements in its stock prices over the past few weeks. This article aims to provide a comprehensive overview of the news updates surrounding Aeterna Zentaris Inc, highlighting its stock performance, key announcements, and return on assets (ROA). Additionally, we will analyze t...
Merger and Acquisition

Innovative Merger: Aeterna Zentaris and Ceapro Unite to Lead Biopharmaceutical Industry

Published Mon, Jun 3 2024 1:16 PM UTC

TORONTO and EDMONTON, Alberta, June 03, 2024 - Aeterna Zentaris Inc. and Ceapro Inc. have officially completed their merger transaction, marking a significant milestone in the biopharmaceutical industry. The merger, announced in December 2023, brings together two innovative companies to create a stronger, more diversified entity in the market.
Aeterna Zentaris, a leading...
Aeterna Zentaris Inc

AEterna Zentaris Inc. Faces Challenges Despite Favorable ISS Recommendation

Aeterna Zentaris Inc., a leading biopharmaceutical development company, has recently received a favorable recommendation from Institutional Shareholder Services Inc. (ISS), a prominent independent proxy advisory firm. ISS has encouraged securityholders of Aeterna Zentaris, as well as Ceapro Inc., another biopharmaceutical development company, to vote in favor of the all-stock merger of equals transaction between the two companies. This merger, which was announced on December 14, 2023, aims to create a diversified biopharmaceutical company and has garnered significant attention within the industry. If successful, it has the potential to reshape the landscape of the biopharmaceutical sector.
Aeterna Zentaris Inc. and Ceapro Inc. are both renowned biopharmaceutical development companies. Aeterna Zentaris Inc. currently has approximately 4.855876 million shares outstanding, with a stock price of $1.89.
Stock Market Announcement

ISS Recommends Shareholders' Approval for Aeterna Zentaris and Ceapro's Merger, Paving the Way for a Diversified Biopharmaceutical Powerhouse

Published Mon, Feb 26 2024 12:30 PM UTC



Leading biopharmaceutical development companies, Aeterna Zentaris Inc. and Ceapro Inc., have received favorable recommendations from Institutional Shareholder Services Inc. (ISS), a prominent independent proxy advisory firm. ISS has recommended that securityholders of both companies vote in favor of the all-stock merger of equals transaction, aimed at creating a di...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com